AstraZeneca: Carcinoma, Renal Cell trials
The registry lists 15 Carcinoma, Renal Cell studies with AstraZeneca as lead sponsor. 2 are open to participants now and 5 have results posted.
Phase 1 7Phase 2 6Phase 3 2No phase 2(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- DESTINY-PANTUMOUR04RecruitingNCT07124000
- A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid TumorsRecruitingNCT07115043Phase 1/2
- Savolitinib vs. Sunitinib in MET-driven PRCC.Active, not recruitingNCT03091192Phase 3Results posted
- A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC)CompletedNCT02127710Phase 2Results posted
- A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Participants With Select Advanced MalignanciesCompletedNCT02118337Phase 1/2Results posted
- Cediranib (AZD2171, RECENTIN™) in Metastatic or Recurrent Renal Cell CarcinomaCompletedNCT00423332Phase 2Results posted
- A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued.CompletedNCT00378482Phase 2Results posted
- Real World Study of Effectiveness of Sunitinib or Sorafenib to Chinese Unresectable Locally Advanced or Metastatic PRCCCompletedNCT07024680
- A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCCActive, not recruitingNCT07000149Phase 1
- A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid TumoursActive, not recruitingNCT06147037Phase 1
- Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCCActive, not recruitingNCT05043090Phase 3
- A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell CarcinomaActive, not recruitingNCT04522323Phase 1
- First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid TumoursCompletedNCT04504669Phase 1
- Dose-Finding Study Of CP-675,206 And SU011248 In Patients With Metastatic Renal Cell CarcinomaCompletedNCT00372853Phase 1
- Exploratory Study to Assess the Biological Activity of ZD6126 in Subjects With Newly Diagnosed Metastatic Renal Cell Carcinoma (Stage IV)SuspendedNCT00065572Phase 2